The involvement of fibroblast growth factor receptor signaling pathways in dermatofibroma and dermatofibrosarcoma protuberans

The Role of CD34 and D2-40 in the Differentiation of Dermatofibroma and Dermatofibrosarcoma Protuberans.

OBJECTIVE Dermatofibroma (DF) is a benign fibrohistiocytic tumor whereas dermatofibrosarcoma protuberans (DFSP) has intermediate malignant potential. CD34 is the most commonly used antibody in differentiating these tumors. Various studies have stated the rates of D2-40 expression as 0-50% in DFSPs and 86-100% in DFs. Our aim in this study was to determine the expression of CD34 and D2-40 in DFs...

Dermatofibrosarcoma Protuberans in Childhood

Dermatofibrosarcoma protuberans.

Overview The NCCN Non-Melanoma Skin Cancer Panel has developed these guidelines outlining the treatment of dermatofibrosarcoma protuberans (DFSP) to supplement their other guidelines (NCCN Clinical Practice Guidelines in Oncology [NCCN Guidelines] for Basal Cell and Squamous Cell Skin Cancers and Merkel Cell Carcinoma; to view the most recent version of these guidelines, visit the NCCN Web site...

Dermatofibrosarcoma Protuberans of The Face:

We report on a patient who presented on the ear, nose and throat (ENT) clinic with swelling on the right temporal region. Imaging studies revealed an expansive process of the skin and subcutaneous tissues of the right preauricular region. Post intravenous contrast administration revealed an ovoid mass with high enhancement without affecting the parotid gland. The patient underwent tumor resecti...

Dermatofibrosarcoma protuberans in childhood.

Dermatofibrosarcoma protuberans (DFSP) is a rare cutaneous tumor with a possibly misleading presentation. It is rare in childhood. We report an 18-month-old child with an acquired atrophic plaque of the left ankle. Based on clinical findings, initial proposed diagnoses included localized scleroderma and localized lipoatrophy. At the age of 5 years the plaque had increased in size and become a p...